Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-04
-
Synaptic scaling up is induced within primary visual cortex
2024-09-14
Synaptic scaling up is induced within primary visual hiv integrase inhibitor (V1) by brief sensory deprivation (Desai et al., 2002; Lambo and Turrigiano, 2013). Several studies have examined the transcriptional changes within extracts of V1 following visual deprivation protocols (Lachance and Chaudh
-
latrunculin a br Materials and methods br Results
2024-09-14
Materials and methods Results Discussion Prostate cancer is the most common cancer in men in the United States and the second leading cause of cancer death. Therapeutic interventions include mainly: radical prostatectomy or radiation therapy (RT), with or without androgen deprivation therap
-
ALK fusion positive NSCLC is
2024-09-14
ALK fusion-positive NSCLC is clinically actionable because it can be targeted by several FDA-approved drugs, including the first generation TKI crizotinib, which is a dual inhibitor to MET and ALK [15], and the second generation inhibitors, alectinib and ceritinib, both of which are highly-selective
-
Growing evidence indicates that GRKs can exert different eff
2024-09-14
Growing evidence indicates that GRKs can exert different effects within the cell depending on the stimulus, cell type, and localization [97], [121]. In this sense, we were the first to demonstrate a mitochondrial localization for GRK2 [122], later confirmed by other investigators [123], establishing
-
SIS3 The overall adjustment the non toxicity
2024-09-14
The overall adjustment, the non-toxicity and the addiction-free treatment methods are the advantages of EA. EA treatment for depression has achieved great clinical effect in recent years (Dong et al., 2017). The clinical practice guideline of the American college of physicians (ACP) have pointed out
-
chir99021 br There is evidence to suggest that GMF activitie
2024-09-14
There is evidence to suggest that GMF activities are regulated in vivo by post-translational modification. indeed, there is strong precedent for ADF-homology family proteins being regulated in this manner. Cofilin is inhibited by phosphorylation of a serine residue at its N terminus. This residue
-
For some fishstocks landed by
2024-09-13
For some fishstocks landed by FMA3 ACE fishers, the designated Quota Management Area (QMA) extends beyond the geographic demarcations of FMA3.Fig. 1 shows the ten FMAs, highlighting the study area FMA3. Gurnard 3 QMA is included as an example of a QMA that CGP 35348 synthesis extends across more th
-
The present study showed for
2024-09-13
The present study showed, for the first time, that hirsutine, hirsuteine, rhynchophylline, isorhynchophylline, corynoxeine, and isocorynoxeine in yokukansan can inhibit the 5-HT3 receptor current. These data indicate that part of the effect of yokukansan against the behavioral and psychological symp
-
The exact etiology of BPH is not completely understood
2024-09-13
The exact etiology of BPH is not completely understood, however this pathology has been associated with elevated estrogen related receptor levels of the androgen DHT (10). Thus, a valuable strategy in BHP treatment is the reduction of DHT (10) levels, by inhibiting its biosynthetic production [6],
-
In this scenario the receptor tyrosine kinase inhibitors TKI
2024-09-13
In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5mo, respectively, hazard ratio (HR) = 0.42; 95% CI: 0.32–0.54; Pits cdc42 i
-
br Acknowledgements This work was supported by the Victorian
2024-09-13
Acknowledgements This work was supported by the Victorian Government Operational Infrastructure Support Program. KAB is supported by the Mavis Robertson Fellowship from the National Breast Cancer Foundation (NBCF; ECF-16-004), by an NBCF Novel Concept Award (NC-14-011), and by NHMRC project grant
-
Citral or dimethyl octadien al is a mixture
2024-09-13
Citral or 3,7-dimethyl-2,6-octadien-1-al is a mixture of two stereoisomeric monoterpene aldehydes (the trans isomer geranial, citral A (40–62%)) and the cis isomer neral, citral B (25–38%) and serves one of the main constituent of essential oils of C. citratusis used in cosmetic, food, fungicides, p
-
As the experimental procedure used could
2024-09-13
As the experimental procedure used could reflect agonist-stimulation of both anterograde and retrograde APJ trafficking, as has been described for the δ-opioid peptide receptor (Zhang et al., 2006b, Zhang et al., 2006a), receptor internalization was more directly monitored by loading cell surface HA
-
APJ receptors have a amino acid sequence
2024-09-13
APJ receptors have a 380 amino iniparib sequence with a characteristic G-protein structure, including seven transmembrane domains and post-translation modification sites for phosphorylation, palmitoylation and glycosylation along with association sites for β-arrestin (O'Dowd et al., 1993). APJ rece
-
br STAR Methods br Author Contributions br Acknowledgments W
2024-09-13
STAR★Methods Author Contributions Acknowledgments We thank Craig D. Wenger and Neva C. Durand for helpful advice, guidance, and discussions. D.H.P. is supported by the NIH National Human Genome Research Institute (NHGRI) (grant R00HG008662) and the Damon Runyon Cancer Research Foundation (D
15688 records 82/1046 page Previous Next First page 上5页 8182838485 下5页 Last page